acquired
Stage
About
KalVista Pharmaceuticals develops orally-delivered small molecule therapies primarily for the treatment of hereditary angioedema (HAE), aiming to improve disease management and patient outcomes in rare diseases.
Explore KalVista's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.